Privi Speciality Chemicals Limited (PRIVISCL)
Micro CapChemicals stocks · Micro cap · NSE
Privi Speciality Chemicals is India's leading manufacturer of aroma chemicals, with a 30+ year track record in pine-based and specialty products. It supplies top fragrance and FMCG companies globally, leveraging 7 manufacturing facilities, 2 R&D centers, and 70% renewable raw materials.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Investable fundamentals, management trust is supportive, price trend is neutral, and recent execution is consistent.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 30 Jun 2026
Good · 67/100Rev +19% YoY · PAT +43% YoY · operating leverage · margin compression
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹666 Cr | +19.1% | -7.8% |
| EBITDA | ₹152 Cr | +15.2% | -15.6% |
| Operating margin | 23.0% | -100 bps | -200 bps |
| PAT | ₹83 Cr | +43.1% | -11.7% |
| PAT margin | 12.5% | +208 bps | -56 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Where growth can come from, and what can break the case
Privi Speciality Chemicals reported strong FY26 performance with total income up 21.7% YoY to 2,583 Cr and PAT up 75.2% YoY to 327.54 Cr. Q4FY26 also saw robust growth, with total income up 15.5% YoY and PAT up 40.9% YoY, driven by volume growth and improved product mix.
Strong FY26 financial performance, including significant revenue and PAT growth, improved margins, and substantial debt reduction, supports the ongoing investment thesis. Management's 5k:1k vision and strategic initiatives like the PRIGIV JV indicate continued growth potential and focus on value-added products.
Existing Product Expansion
Expanding the reach of current products to increase sales.
New Product Innovation
Introducing new products, in synergy with existing raw materials, including Maltol, Ethyl Maltol, Renewable Cyclopentanone, and Furfural.
PRIGIV Joint Venture
Dedicated product portfolio manufacturing 40+ specialty products exclusively for Givaudan, achieved positive PAT in Q4 FY26.
Biotech-Focused R&D
Privi Biotechnologies Private Limited (PBPL) specializes in biotechnology-driven flavour and fragrance development, aligning with green science vision.
Debottlenecking Initiatives
Undertook debottlenecking initiatives in FY26 to support future growth and enhance capacity utilization.
PRIGIV Plant Commissioning
PRIGIV JV commissioned and commenced commercial production at Mahad, MH.
Specialty Molecule Expansion
Evaluating additional CAPEX to manufacture high-value specialty molecules using in-house technology, with potential revenue of ~ 100+ crore.
Flagship Product Augmentation
Flagship product capacity augmentation project nearing completion.
Growing Urbanization and Lifestyle Upgrade
Rising urbanization and changing consumer lifestyles are boosting the consumption of fragrance-based products.
Shift towards Sustainable Ingredients
Preference for bio-based and eco-friendly aroma chemicals is reshaping product innovation and market positioning.
Expanding Asian & Emerging Markets
Rising affluence and premiumization are driving fragrance usage in personal care and home care.
Management accountability
What management said, and what results must prove
Management accountability
What management said, and what results must prove
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
The presentation provides both quarterly (Q4FY26 vs Q4FY25) and annual (FY26 vs FY25) comparisons. Annual figures are crucial for assessing overall business trajectory and the impact of strategic initiatives, while quarterly data shows recent momentum.
Total Income
FY26: 2,582.92 Cr (+21.7% YoY); Q4FY26: 725.70 Cr (+15.5% YoY)
EBITDA Margin
FY26: 25.8% (+342 bps YoY); Q4FY26: 25.4% (+195 bps YoY)
PAT
FY26: 327.54 Cr (+75.2% YoY); Q4FY26: 93.7 Cr (+40.9% YoY)
Operating Cash Flow
FY26: 550.09 Cr
5k:1k Vision
Focused on disciplined execution and delivering on the 5k:1k vision ( 5,000 Cr revenue and 1,000 Cr+ EBITDA) over the medium term (by FY29-30).
Profitability Focus
Strong emphasis on profitability and long-term value creation, with EBITDA margins expected to sustain north of 20%.
Value-Added & Specialty Products
Continue to see encouraging traction in value-added and specialty products, supported by focused investments in capability building.
Sustainability Integration
Sustainability remains integral to the approach, with continued emphasis on responsible manufacturing and process innovation.
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Revenue | 2,582.92 Cr (FY26) | Progress towards 5,000 Cr by FY29-30. |
| EBITDA | 665.45 Cr (FY26) | Progress towards 1,000 Cr+ by FY29-30. |
| EBITDA Margin | 25.8% (FY26) | Sustained margins north of 20%. |
| Net Debt to Equity | 0.62x (FY26) | Continued reduction in debt levels. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trend score and candlestick chart
49NeutralSMA20 -5.1% / mo · MACD −
Technical chart
PRIVISCLdaily · 1Y · AUTO+15.3%Daily technical trend read
Bearish setupTrend is weak — long-term uptrend intact. RSI 35.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~5.3% over last month) — short-term momentum negative.
- RSI(14) at 35 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 11% off 52W high · 51% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation & score drivers
U-Score 65 · UNDERVALUED · pillar breakdown, sector model, fair-value anchor
Valuation & score drivers
U-Score 65 · UNDERVALUED · pillar breakdown, sector model, fair-value anchor
Fundamental score breakdown
UNDERVALUEDWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 16.4%.
- Quality contributes 20/20 to the score.
Main drags
- Valuation is weaker at 4/30; verify the latest quarterly trend.
- Cash flow is weaker at 5/10; verify the latest quarterly trend.
- Balance sheet is weaker at 8/15; verify the latest quarterly trend.
Cyclical valuation: normalized earnings, not just trailing PE
Cyclical companies can look cheapest near peak profits, so IndiaPulse flags value-trap risk separately.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: +0 points.
Factor attribution
Modelled fair value
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Healthy Trust: Claim history is still being built. It ranks around the 94th percentile of the scored universe and 91st percentile within Chemicals. No major sub-score weakness stands out.
High Trust Lite: Promoter holding is 60.6%. Key concern: Promoter holding fell 9.3%.
Generally investable credibility. Look for weak sub-scores before increasing position size.
overall median 67 · Chemicals: 91st pctile, median 73 · Micro: 90th pctile, median 73
56 documents have extracted text, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Healthy Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter holding is 60.6%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 1.5%.
- ▸5 years of positive FCF.
Trust risks
- ▸Promoter holding fell 9.3%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Fundamentals
Valuation
- P/E
- 37.60
- P/B
- 9.33
- EV/EBITDA
- 17.48
- Market Cap
- 13154.00Cr
Profitability
- ROE
- 26.00%
- ROCE
- 22.30%
- ROA
- 10.79%
- Dividend Y
- 0.30%
Growth (CAGR)
- Revenue 5Y
- 15.00%
- EPS 5Y
- 27.00%
- Revenue 3Y
- 17.00%
- EPS 3Y
- 67.50%
Balance Sheet
- Debt/Equity
- 0.72
- Interest Coverage
- 8.88×
- Altman Z
- 6.79
- Book Value
- 361.00
Cash Flow
- FCF Yield
- 1.46%
- FCF Positive Y
- 5/5
- OCF
- 550.00 Cr
- EPS TTM
- 89.47
Shareholding
- Promoter Hold
- 60.60%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 73%
Financial History
Updated 5/9/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable names in Chemicals, ranked by similarity
Peers
Business-comparable names in Chemicals, ranked by similarity
Peers
Business-comparable peers in Chemicals — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.